2023 World Conference on Lung Cancer (Posters)-EP11.03. Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China

EP11.03. Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China - PDF(Slides)

Back to course

Pdf Summary

A small retrospective study conducted in China aimed to evaluate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, combined with chemotherapy in Chinese patients with advanced lung cancer harboring KRAS mutations. The study included 10 patients who received tislelizumab plus nab-paclitaxel and platinum-based chemotherapy for up to 4-6 cycles, followed by tislelizumab maintenance therapy. The primary endpoint was the objective response rate (ORR), with secondary endpoints including time to treatment failure (TTF), overall survival (OS), and safety.<br /><br />The results showed that as of the data cutoff in March 2023, the ORR was 66.7% and the disease control rate (DCR) was 77.8%. The median TTF was 10.5 months, and the median OS was 12.5 months. Adverse events were mostly grade 1 or 2, with leukopenia, rash, and fatigue being the most common. No grade 4 or 5 treatment-related adverse events were observed.<br /><br />The study concluded that tislelizumab combined with nab-paclitaxel and platinum-based chemotherapy demonstrated a promising trend of anti-tumor efficacy with a manageable safety profile in Chinese patients with advanced lung cancer harboring KRAS mutations. However, it is important to note that this was a small retrospective study, and further research is needed to validate these findings.

Asset Subtitle

Fengnan Wang

Meta Tag

Speaker Fengnan Wang

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

China

efficacy

safety

tislelizumab

chemotherapy

lung cancer

KRAS mutations

adverse events

anti-tumor efficacy